• Explore /
  • Poster
  • / A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (MDM2-p53 antagonist) in adult patients with advanced or metastatic solid tumors.

A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (MDM2-p53 antagonist) in adult patients with advanced or metastatic solid tumors.

Abstract Poster

Authors

null

Curtis Robert Chong

Memorial Sloan Kettering Cancer Center, New York, NY

Curtis Robert Chong , Todd Michael Bauer , Scott Andrew Laurie , Manish R. Patel , Noboru Yamamoto , Teffany Davenport , Junxian Geng , Neil Gibson , Markus P. Vallaster , Patricia LoRusso

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics and Tumor Biology (Nonimmuno)

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Other Developmental Therapeutics

Clinical Trial Registration Number

NCT03449381

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS3166)

DOI

10.1200/JCO.2019.37.15_suppl.TPS3166

Abstract #

TPS3166

Poster Bd #

148a

Abstract Disclosures

Similar Posters

Poster

2020 ASCO Virtual Scientific Program

Results of a completed first-in-human phase Ib dose-escalation study of oral CBL0137 in patients with advanced solid tumors.

Results of a completed first-in-human phase Ib dose-escalation study of oral CBL0137 in patients with advanced solid tumors.

First Author: Mikhail Fedyanin

First Author: Judy S. Wang

First Author: Alexander Peltzer

First Author: Patricia LoRusso